Trial reportClinical lymphoma, myeloma & leukemia2015
Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Trial report in Clinical lymphoma, myeloma & leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 83 citations in OpenAlex.
- Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.Clinical lymphoma, myeloma & leukemia · 2017Trial
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.Journal of hematology & oncology · 2017Trial
- Trial
- Dyslipidaemias in cancer patients.European heart journal · 2026Review
- Glucose transport dependency defines a therapeutic vulnerability in JAK2V617F-driven myeloproliferative neoplasms.Cell communication and signaling : CCS · 2026Article
- Modern and multidisciplinary care in polycythemia vera.Annals of hematology · 2026Review
- JAK inhibitors for the treatment of juvenile localized scleroderma: a case report and literature review.Pediatric rheumatology online journal · 2026Review
- Patient-reported outcomes regarding the use of complementary and alternative medicine (CAM) in BCR::ABL1-negative myeloproliferative neoplasias.Journal of cancer research and clinical oncology · 2026Article
- Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.Frontiers in oncology · 2026Review
- Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic Landscape.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Malignant JAK-signaling: at the interface of inflammation and malignant transformation.Leukemia · 2025Review
- Prognostic Implications of Red Blood Cell Distribution Width to Albumin Ratio in Myelofibrosis: A 10-Year Multicenter and Retrospective Study.Journal of inflammation research · 2025Article
- Diabetes mellitus, metformin, and the risk of MPN.Blood advances · 2024Article
- Cardiovascular Considerations in Patients Undergoing Hematopoietic Cell Transplantation.Current treatment options in oncology · 2024Review
- Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms.World journal of clinical oncology · 2024Review
- SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera.Clinical lymphoma, myeloma & leukemia · 2024Review
- Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib.JCO precision oncology · 2024Article
- Article
- Rapid Resolution of Life-Threatening Hypertriglyceridemia after Evinacumab Administration in a Pediatric HSCT Recipient: A Case Report.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.Journal of hematology & oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundIn the COMFORT (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy)-I study, the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib provided significant reductions in splenomegaly, improvements in myelofibrosis (MF)-related symptoms, and a survival advantage relative to placebo in patients with intermediate-2 or high-risk MF. In this post hoc analysis, we assessed the effects of ruxolitinib treatment on measures of metabolic and nutritional status. PATIENTS AND
methodsPatients were randomized to receive ruxolitinib (n = 155; 15 or 20 mg twice a day for patients with baseline platelet counts of 100-200 × 10(9)/L or > 200 × 10(9)/L, respectively) or placebo (n = 154). The primary end point was the proportion of patients with a ≥ 35% spleen volume reduction from baseline to week 24. A secondary end point was the proportion of patients with ≥ 50% improvement in Total Symptom Score (TSS) from baseline to week 24, measured using the modified Myelofibrosis Symptom Assessment Form version 2.0. Weight, cholesterol, and albumin were measured at specified time points throughout the study.
resultsCompared with placebo, ruxolitinib treatment was associated with increased weight (mean change: 3.9 kg vs. -1.9 kg), total cholesterol (mean percentage change: 26.4% vs. -3.3%), and albumin levels (mean percentage change: 5.8% vs. -1.7%) at week 24; sustained improvements were observed with longer-term ruxolitinib therapy. Relative to placebo, increases in mean weight, total cholesterol, and albumin levels were observed with ruxolitinib treatment regardless of the degree of spleen volume and TSS reductions at 24 weeks.
conclusionTreatment with ruxolitinib improved measures of metabolic and nutritional status of patients with intermediate-2 or high-risk MF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.